Altogen Labs was founded in 2009, with an initial GLP-compliant facility. The company specialized in xenograft models and their use in preclinical drug development, focusing on the delivery of nucleic acids into rodents as part of gene therapy testing.
The company has two subsidiaries; a Las Vegas, Nevada transfection-focused division, Altogen Biosystems, that manufactures cell line-specific reagents based on liposomes and polymers, and a chemical subsidiary, Altogen Chemicals, which manufactures organic compounds and hexachlorodisilane.
- Miles, Jonathan (April 2017). "Medical Discovery and Innovation Preclinical Contract Research Services by Altogen Labs". GHP Magazine: 1–15.
- Lorek, Laura (31 January 2013). "11 Startups Join Texas Venture Lab's Spring 2013 Accelerator". Silicon Hills News. Retrieved 1 July 2018.
- Roberts, Josh P. (12 August 2014). "Primary Cells Pose No Problem with These Transfection Tools". Biocompare. Retrieved 1 July 2018.
- Blow, Nathan (13 December 2007). "Small RNAs: Delivering the future". Nature. 450: 1117–1120. doi:10.1038/4501117a.
- "New Products". Science. 330 (6011): 1700. 17 December 2010. doi:10.1126/science.330.6011.1700-a.
- Ranjan, Vishal (3 June 2016). "Altogen Chemicals Launches Ultra-pure Hexachlorodisilane". Researz. Retrieved 1 July 2018.
This article "Altogen Labs" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Altogen Labs. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.